Amundi Pioneer Asset Management Inc. Takes Position in Iqvia Holdings Inc (IQV)
Amundi Pioneer Asset Management Inc. purchased a new position in shares of Iqvia Holdings Inc (NYSE:IQV) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 277,293 shares of the medical research company’s stock, valued at approximately $27,147,000.
Several other institutional investors have also recently added to or reduced their stakes in IQV. BlackRock Inc. bought a new position in shares of Iqvia during the fourth quarter worth about $942,532,000. Longview Partners Guernsey LTD bought a new position in shares of Iqvia during the fourth quarter worth about $927,548,000. Jackson Square Partners LLC bought a new position in shares of Iqvia during the fourth quarter worth about $464,053,000. Alliancebernstein L.P. bought a new position in shares of Iqvia during the fourth quarter worth about $253,128,000. Finally, Geode Capital Management LLC bought a new position in shares of Iqvia during the fourth quarter worth about $151,538,000. Institutional investors and hedge funds own 91.77% of the company’s stock.
In other Iqvia news, Director Michael J. Evanisko sold 816 shares of the company’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $100.00, for a total value of $81,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James H. Erlinger III sold 10,000 shares of the company’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $99.97, for a total transaction of $999,700.00. The disclosure for this sale can be found here. Insiders sold a total of 30,816 shares of company stock valued at $3,093,400 over the last three months. 6.40% of the stock is owned by corporate insiders.
Iqvia (NYSE:IQV) last announced its earnings results on Wednesday, February 14th. The medical research company reported $1.32 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.34 by ($0.02). Iqvia had a net margin of 13.44% and a return on equity of 13.03%. The company had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same quarter in the prior year, the company earned $1.09 EPS. The business’s quarterly revenue was up 10.7% on a year-over-year basis. equities analysts forecast that Iqvia Holdings Inc will post 2.84 earnings per share for the current fiscal year.
Several equities analysts have recently commented on the stock. SunTrust Banks upgraded shares of Iqvia from a “hold” rating to a “buy” rating in a research report on Wednesday, March 7th. Zacks Investment Research lowered shares of Iqvia from a “buy” rating to a “hold” rating in a research report on Friday, January 19th. ValuEngine upgraded shares of Iqvia from a “hold” rating to a “buy” rating in a research report on Tuesday, February 20th. JPMorgan Chase & Co. upped their price target on shares of Iqvia from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Finally, Piper Jaffray Companies reiterated a “hold” rating and issued a $103.00 target price on shares of Iqvia in a research report on Thursday, February 15th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Iqvia presently has an average rating of “Buy” and an average target price of $110.02.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/03/12/amundi-pioneer-asset-management-inc-takes-position-in-iqvia-holdings-inc-iqv.html.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.